<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Tramadol</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00193</strong>&#160; (APRD00028)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>A narcotic analgesic proposed for moderate to severe pain. It may be habituating. [PubChem] Tramadol is also prepared as a variable release capsules, marketed under the brand name ConZip. For example, a 150 mg capsule will contain 37.5 mg of the immediate release form and 112.5 mg of the extended release form.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00193/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00193/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00193.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00193.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00193.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00193.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00193.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00193">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Tramadol Hydrochloride </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000181/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000181/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: PPKXEPBICJTCRU-XMZRARIVSA-N</li>
              <li>Monoisotopic Mass: 299.165206788</li>
              <li>Average Mass: 299.836</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000181">DBSALT000181</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>ConZip</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Durela</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ralivia</td><td>Biovail</td></tr><tr><td>Rybix</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ryzolt</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tramal</td><td>Gr&#252;nenthal GmbH</td></tr><tr><td>Tridural</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ultram</td><td>Janssen Pharmaceuticals</td></tr><tr><td>Zytram XL </td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Tramacet </td><td>Acetaminophen and Tramadol </td></tr><tr><td>ULTRACET</td><td>Tramadol + Acetaminophen</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>27203-92-5</td></tr><tr><th>Weight</th><td>Average: 263.3752<br>Monoisotopic: 263.188529049</td></tr><tr><th>Chemical Formula</th><td>C<sub>16</sub>H<sub>25</sub>NO<sub>2</sub></td></tr><tr><th>InChI Key</th><td>TVYLLZQTGLZFBW-ZBFHGGJFSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenol Ethers</td></tr><tr><th>Direct parent</th><td>Anisoles</td></tr><tr><th>Alternative parents</th><td>Alkyl Aryl Ethers; Cyclohexanols; Tertiary Alcohols; Tertiary Amines; Cyclic Alcohols and Derivatives; Polyamines</td></tr><tr><th>Substituents</th><td>cyclohexanol; alkyl aryl ether; tertiary alcohol; cyclic alcohol; tertiary amine; ether; polyamine; alcohol; organonitrogen compound; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the anisoles. These are organic compounds contaiing a methoxybenzene or a derivative thereof.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Indicated in the treatment of moderate to severe pain. Consider for those prone to constipation or respiratory depression. Tramadol is used to treat postoperative, dental, cancer, and acute musculosketetal pain and as an adjuvant to NSAID therapy in patients with osteoarthritis.</td></tr><tr><th>Pharmacodynamics</th><td>Tramadol, a centrally-acting analgesic, exists as a racemic mixture of the <i>trans</i> isomer, with important differences in binding, activity, and metabolism associated with the two enantiomers. Although its mode of action is not completely understood, from animal tests, at least two complementary mechanisms appear applicable: binding of parent and M1 metabolite to &#956;-opioid receptors and weak inhibition of reuptake of norepinephrine and serotonin. Opioid activity is due to both low affinity binding of the parent compound and higher affinity binding of the O-demethylated metabolite M1 to &#956;-opioid receptors. In animal models, M1 is up to 6 times more potent than tramadol in producing analgesia and 200 times more potent in &#956;-opioid binding. Opiate antagonist naloxone only partially antagonized tramadol-induced analgesia. </td></tr><tr><th>Mechanism of action</th><td>Tramadol and its O-desmethyl metabolite (M1) are selective, weak OP3-receptor agonists. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. The analgesic properties of Tramadol can be attributed to norepinephrine and serotonin reuptake blockade in the CNS, which inhibits pain transmission in the spinal cord. The (+) enantiomer has higher affinity for the OP3 receptor and preferentially inhibits serotonin uptake and enhances serotonin release. The (-) enantiomer preferentially inhibits norepinephrine reuptake by stimulating alpha(2)-adrenergic receptors.</td></tr><tr><th>Absorption</th><td>Racemic tramadol is rapidly and almost completely absorbed after oral administration. The mean absolute bioavailability of a 100 mg oral dose is approximately 75%. The mean peak plasma concentration of racemic tramadol and M1 occurs at two and three hours, respectively, after administration in healthy adults.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>2.6 L/kg [male, 100 mg intravenous dose]</li>
	<li>2.9 L/kg [female, 100 mg intravenous dose]</li>
</ul></td></tr><tr><th>Protein binding</th><td>20% bound to plasma proteins. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. The major metabolic pathways appear to be N- and O- demethylation and glucuronidation or sulfation in the liver. One metabolite (O-desmethyltramadol, denoted M1) is pharmacologically active in animal models. CYP3A4 and CYP2B6 facilitates the biotransformation of tramadol to N-desmethyl-tramadol. CYP2D6 facilitates the biotransformation of tramadol to O-desmethyl-tramadol.  </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Tramadol</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li></ul></td><td><a href="/metabolites/DBMET00324">O-Desmethyltramadol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/325">Details</a></td></tr><tr><td>Tramadol</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00343">N-Desmethyltramadol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/345">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00324">O-Desmethyltramadol</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003679" target="_blank">UDP-glucuronosyltransferase 2B7</a></li>
<li><a href="/biodb/bio_entities/BE0003682" target="_blank">UDP-glucuronosyltransferase 1-8</a></li></ul></td><td><a href="/metabolites/DBMET00966">O-Desmethyl-tramado glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1209">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00324">O-Desmethyltramadol</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li></ul></td><td><a href="/metabolites/DBMET00957">N,O-didesmethyltramadol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1210">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00343">N-Desmethyltramadol</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li></ul></td><td><a href="/metabolites/DBMET00957">N,O-didesmethyltramadol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1211">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00343">N-Desmethyltramadol</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li></ul></td><td><a href="/metabolites/DBMET00954">N,N-didesmethyltramadol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1212">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00957">N,O-didesmethyltramadol</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00956">N,N,O-tridesmethyl-tramadol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1213">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00954">N,N-didesmethyltramadol</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00956">N,N,O-tridesmethyl-tramadol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1214">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Tramadol is eliminated primarily through metabolism by the liver and the metabolites are excreted primarily by the kidneys. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% of the dose is excreted as metabolites.</td></tr><tr><th>Half life</th><td>Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.</td></tr><tr><th>Clearance</th><td><ul>
	<li>5.9 mL/min/Kg [Healthy Adults, 100 mg qid, MD p.o]</li>
	<li>8.5 mL/min/Kg [Healthy Adults, 100 mg SD p.o]</li>
	<li>6.89 mL/min/Kg [Geriatric, (&lt;75 yr), 50 mg SD p.o.]</li>
	<li>4.23 mL/min/Kg [Hepatic Impaired, 50 mg SD p.o.]</li>
	<li>4.23 mL/min/Kg [Renal Impaired, Clcr10-3mL/min, 100 mg SD i.v.]</li>
	<li>3.73 mL/min/Kg [Renal Impaired, CLcr&lt;5 mL/min, 100 mg SD i.v.]</li>
	<li>6.4 mL/min/Kg [Male following a 100 mg IV dose]</li>
	<li>5.7 mL/min/Kg [Female  following a 100 mg IV dose]</li>
</ul></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=350mg/kg (orally in mice)</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th><th>SMPDB ID</th></tr></thead><tbody><tr><td>Tramadol Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00637?highlight%5Bcompounds%5D%5B%5D=DB00193&amp;highlight%5Bproteins%5D%5B%5D=DB00193">SMP00637</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9924</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9382</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8866</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6283</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.7807</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.9589</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6398</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7678</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8919</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7726</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7136</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.704</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.6566</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6841</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6256</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7832</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7899
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.6663
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9975
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.0316 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.6136
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.7098
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Cipher pharmaceuticals inc</li>
<li>Purdue pharma products lp</li>
<li>Par pharmaceutical</li>
<li>Biovail laboratories international srl</li>
<li>Victory pharma inc</li>
<li>Actavis elizabeth llc</li>
<li>Alphapharm party ltd</li>
<li>Amneal pharmaceuticals llc</li>
<li>Apotex inc</li>
<li>Asta medica inc</li>
<li>Caraco pharmaceutical laboratories ltd</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Mallinckrodt inc</li>
<li>Mutual pharmaceutical co inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Northstar healthcare holdings ltd</li>
<li>Pliva inc</li>
<li>Sandoz inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Watson laboratories</li>
<li>Ortho mcneil janssen pharmaceuticals inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.4udr.com">4uOrtho LLC</a></li>
<li><a href="http://www.ablelabs.com">Able Laboratories Inc.</a></li>
<li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.alphapharm.com.au">Alphapharm Party Ltd.</a></li>
<li><a href="http://www.alturapharma.com">Altura Pharmaceuticals Inc.</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.amneal.com">Amneal Pharmaceuticals</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li>Apotheca Inc.</li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li>BC Vision Inc.</li>
<li><a href="http://www.biovail.com">Biovail Pharmaceuticals</a></li>
<li><a href="http://www.bpipack.com">Blenheim Pharmacal</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.caraco.com">Caraco Pharmaceutical Labs</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.stirol.net">Concern Stirol</a></li>
<li><a href="http://www.confab.ca">Confab Laboratories Inc.</a></li>
<li><a href="http://www.corepharma.com">Corepharma LLC</a></li>
<li>Coupler Enterprises Inc.</li>
<li>D.M. Graham Laboratories Inc.</li>
<li><a href="http://www.decapharma.com">Deca Pharmaceuticals LLC</a></li>
<li>DHHS Program Support Center Supply Service Center</li>
<li>Direct Dispensing Inc.</li>
<li>DispenseXpress Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li>Eon Labs</li>
<li>Fusion Pharmaceuticals LLC</li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li>Ivax Pharmaceuticals</li>
<li><a href="http://www.janssen-ortho.com">Janssen-Ortho Inc.</a></li>
<li>Kali Laboratories Inc.</li>
<li><a href="http://www.keltman.com">Keltman Pharmaceuticals Inc.</a></li>
<li><a href="http://www.labopharm.com">Labopharm Inc.</a></li>
<li>Lake Erie Medical and Surgical Supply</li>
<li>Liberty Pharmaceuticals</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mallinckrodt.com">Mallinckrodt Inc.</a></li>
<li>McNeil Laboratories</li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.medvantx.com">Medvantx Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li>Mutual Pharmaceutical Co.</li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Novopharm Ltd.</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.ortho-mcneil.com">Ortho Mcneil Janssen Pharmaceutical Inc.</a></li>
<li><a href="http://www.ortho-mcneil.com">Ortho-McNeil-Janssen Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.parpharm.com">Par Pharmaceuticals</a></li>
<li><a href="http://www.patriotpharmaceuticals.com">Patriot Pharmaceuticals</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.piramalpharmasolutions.com">Piramal Healthcare</a></li>
<li><a href="http://www.pliva.com">Pliva Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li>Prescription Dispensing Service Inc.</li>
<li><a href="http://www.purduepharma.com">Purdue Pharma LP</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Redpharm Drug</li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.ropack.com">Ropack Inc.</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li>St Mary's Medical Park Pharmacy</li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Torpharm Inc.</li>
<li><a href="http://www.trinitylab.us">Trinity Laboratories Inc.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.urlpharma.com">United Research Laboratories Inc.</a></li>
<li>Va Cmop Dallas</li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>100 mg, 150 mg, 200 mg, 300 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>50 mg</td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td>100 mg, 200 mg, 300 mg</td></tr><tr><td>Tablet, orally disintegrating</td><td>Oral</td><td>50 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Tramadol hcl powder</td><td>29.08USD</td><td>g</td></tr><tr><td>Ultram ER 300 mg 24 Hour tablet</td><td>10.66USD</td><td>tablet</td></tr><tr><td>Ultram er 300 mg tablet</td><td>10.25USD</td><td>tablet</td></tr><tr><td>Ultram ER 200 mg 24 Hour tablet</td><td>7.64USD</td><td>tablet</td></tr><tr><td>Ultram er 200 mg tablet</td><td>7.35USD</td><td>tablet</td></tr><tr><td>TraMADol HCl 200 mg 24 Hour tablet</td><td>6.25USD</td><td>tablet</td></tr><tr><td>Ultram ER 100 mg 24 Hour tablet</td><td>4.62USD</td><td>tablet</td></tr><tr><td>Ultram er 100 mg tablet</td><td>4.44USD</td><td>tablet</td></tr><tr><td>TraMADol HCl 100 mg 24 Hour tablet</td><td>3.78USD</td><td>tablet</td></tr><tr><td>Ultram 50 mg tablet</td><td>1.99USD</td><td>tablet</td></tr><tr><td>Tramadol-Acetaminophen 37.5-325 mg tablet</td><td>1.07USD</td><td>tablet</td></tr><tr><td>Tramadol hcl 50 mg tablet</td><td>0.7USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>6607748</td><td>2000-06-29</td><td>2020-06-29</td></tr><tr><td>United States</td><td>5464632</td><td>1993-03-22</td><td>2013-03-22</td></tr><tr><td>Canada</td><td>2476201</td><td>2009-09-01</td><td>2023-02-21</td></tr><tr><td>Canada</td><td>2123160</td><td>2003-04-29</td><td>2014-05-09</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>180-181 &#176;C</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>water solubility</td><td>Soluble </td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>2.4</td><td>FDA label </td></tr><tr><td>pKa</td><td>9.41</td><td>FDA label </td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>7.50e-01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.71</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.45</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-2.5</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>13.8</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>9.23</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>32.7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>78.27</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>30.45</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Wolfgang Reimann, &#8220;Combination preparation containing tramadol and a calcium channel antagonist.&#8221; U.S. Patent US5929122, issued March, 1993.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=5929122&amp;tbm=pts" target="_blank">US5929122 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Dayer P, Desmeules J, Collart L: [Pharmacology of tramadol] Drugs. 1997;53 Suppl 2:18-24. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9190321">Pubmed</a></li>
	<li>Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, Donofrio P, Cornblath D, Sachdeo R, Siu CO, Kamin M: Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998 Jun;50(6):1842-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9633738">Pubmed</a></li>
	<li>Harati Y, Gooch C, Swenson M, Edelman SV, Greene D, Raskin P, Donofrio P, Cornblath D, Olson WH, Kamin M: Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications. 2000 Mar-Apr;14(2):65-70. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10959067">Pubmed</a></li>
	<li>Gobel H, Stadler T: [Treatment of post-herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine] Drugs. 1997;53 Suppl 2:34-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9190323">Pubmed</a></li>
	<li>Boureau F, Legallicier P, Kabir-Ahmadi M: Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain. 2003 Jul;104(1-2):323-31. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12855342">Pubmed</a></li>
	<li><span class="caps">FDA</span> label</li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D08623" target="_blank">D08623 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C07153" target="_blank">C07153 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=33741" target="_blank">33741 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46506256" target="_blank">46506256 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.31105.html" target="_blank">31105 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>BindingDB</td><td><a class="wishart-link-out" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50176262" target="_blank">50176262 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000140" target="_blank">DAP000140 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA451735" target="_blank">PA451735 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/tramadol.htm" target="_blank">http://www.rxlist.com/cgi/generic/tramadol.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/tramadol.html" target="_blank">http://www.drugs.com/tramadol.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Tramadol" target="_blank">Tramadol <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>N02AX02<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N02#N02">N02 &#8212; ANALGESICS</a></li><li><a href="/atc/N02A#N02A">N02A &#8212; OPIOIDS</a></li><li><a href="/atc/N02AX#N02AX">N02AX &#8212; Other opioids</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>28:08.08</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00193.pdf?1265922808">show</a>(408 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00193.pdf?1265922745">show</a>(74.7 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00918">Almotriptan</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. </td></tr><tr><td><a href="/drugs/DB06274">Alvimopan</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB00357">Aminoglutethimide</a></td><td>Aminoglutethimide may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Amiodarone may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Amiodarone may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>Tramadol increases the risk of serotonin syndrome and seizures. </td></tr><tr><td><a href="/drugs/DB00543">Amoxapine</a></td><td>Tramadol increases the risk of serotonin syndrome and seizures. </td></tr><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>Amprenavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00673">Aprepitant</a></td><td>Aprepitant may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Atazanavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00865">Benzphetamine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00559">Bosentan</a></td><td>Bosentan may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB01200">Bromocriptine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00248">Cabergoline</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Carbamazepine may decrease the effect of tramadol by increasing Tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB00608">Chloroquine</a></td><td>Chloroquine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00477">Chlorpromazine</a></td><td>Chlorpromazine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Cimetidine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Cimetidine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB01012">Cinacalcet</a></td><td>Cinacalcet may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00215">Citalopram</a></td><td>The use of two serotonin modulators, such as citalopram and tramadol, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Clarithromycin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>Tramadol increases the risk of serotonin syndrome and seizures. Clomipramine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00257">Clotrimazole</a></td><td>Clotrimazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>Clozapine may decrease the effect of Tramadol by decreasing active metabolite production. 
</td></tr><tr><td><a href="/drugs/DB00907">Cocaine</a></td><td>Cocaine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>Conivaptan may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00924">Cyclobenzaprine</a></td><td>Increases risk of seizure. </td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Cyclosporine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB00496">Darifenacin</a></td><td>Darifenacin may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB01264">Darunavir</a></td><td>Darunavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>Delavirdine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Delavirdine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>Tramadol increases the risk of serotonin syndrome and seizures. Desipramine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Desipramine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB06700">Desvenlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01234">Dexamethasone</a></td><td>Dexamethasone may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB01576">Dextroamphetamine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00514">Dextromethorphan</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>Diltiazem may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB01075">Diphenhydramine</a></td><td>Diphenhydramine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>Tramadol increases the risk of serotonin syndrome and seizures. </td></tr><tr><td><a href="/drugs/DB00476">Duloxetine</a></td><td>Duloxetine may decrease the effect of Tramadol by decreasing active metabolite production. Increased risk of serotonin syndrome. Monitor for Tramadol efficacy and symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00625">Efavirenz</a></td><td>Efavirenz may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00216">Eletriptan</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01049">Ergoloid mesylate</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01253">Ergonovine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Erythromycin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB01175">Escitalopram</a></td><td>Tramadol may increase the risk of serotonin syndrome and seizures.</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Tramadol,when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration and efficacy due to increased tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Fluconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>The use of two serotonin modulators, such as fluoxetine and tramadol, may increase the risk of serotonin syndrome. Fluoxetine may decrease the effect of tramadol by decreasing active metabolite production.</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Tramadol may increase the risk of serotonin syndrome and seizures.</td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>Fosamprenavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Fosphenytoin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00998">Frovatriptan</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00614">Furazolidone</a></td><td>Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Furazolidone. </td></tr><tr><td><a href="/drugs/DB00502">Haloperidol</a></td><td>Haloperidol may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Haloperidol may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>Imatinib may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Imatinib may decrease the effect of Tramadol by decreasing active metabolite production.  </td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>Tramadol increases the risk of serotonin syndrome and seizures. Imipramine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Indinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, isocarboxazid.</td></tr><tr><td><a href="/drugs/DB00951">Isoniazid</a></td><td>Isoniazid may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Isoniazid may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Ketoconazole may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB01259">Lapatinib</a></td><td>Lapatinib may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB00281">Lidocaine</a></td><td>Lidocaine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Lidocaine may decrease the effect of Tramadol by decreasing active metabolite production.</td></tr><tr><td><a href="/drugs/DB00601">Linezolid</a></td><td>Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Linezolid. </td></tr><tr><td><a href="/drugs/DB01255">Lisdexamfetamine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01601">Lopinavir</a></td><td>Lopinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Lopinavir may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00934">Maprotiline</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>Methadone may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB01577">Methamphetamine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01403">Methotrimeprazine</a></td><td>Additive CNS depressant effects. Decrease dose of tramadol by 50% if initiating methotrimeprazine therapy. Monitor for increased CNS depression and apply further dosage adjustments as required. </td></tr><tr><td><a href="/drugs/DB00353">Methylergometrine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00916">Metronidazole</a></td><td>Metronidazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB01110">Miconazole</a></td><td>Miconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Miconazole may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00370">Mirtazapine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01171">Moclobemide</a></td><td>Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, moclobemide.</td></tr><tr><td><a href="/drugs/DB00607">Nafcillin</a></td><td>Nafcillin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00952">Naratriptan</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Nefazodone may increase tramadol toxicity by decreasing tramadol metabolism and clearance. Increased risk of serotonin syndrome. Monitor for tramadol toxicity and symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>Nelfinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00238">Nevirapine</a></td><td>Nevirapine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00622">Nicardipine</a></td><td>Nicardipine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Nicardipine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB04868">Nilotinib</a></td><td>Nilotinib may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB01059">Norfloxacin</a></td><td>Norfloxacin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>Tramadol increases the risk of serotonin syndrome and seizures. </td></tr><tr><td><a href="/drugs/DB00776">Oxcarbazepine</a></td><td>Oxcarbazepine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>Tramadol may increase the risk of serotonin syndrome and seizures. Paroxetine may decrease the effect of Tramadol by decreasing active metabolite production.</td></tr><tr><td><a href="/drugs/DB00312">Pentobarbital</a></td><td>Pentobarbital may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB01186">Pergolide</a></td><td>Pergolide may decrease the effect of Tramadol by decreasing active metabolite production. Increased risk of serotonin syndrome. Monitor for Tramadol efficacy and symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00454">Pethidine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01579">Phendimetrazine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, phenelzine.</td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>Phenobarbital may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00191">Phentermine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Phenytoin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB01132">Pioglitazone</a></td><td>Pioglitazone may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB01263">Posaconazole</a></td><td>Posaconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00794">Primidone</a></td><td>Primidone may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB01168">Procarbazine</a></td><td>Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Procarbazine.</td></tr><tr><td><a href="/drugs/DB01069">Promethazine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00344">Protriptyline</a></td><td>Tramadol increases the risk of serotonin syndrome and seizures. </td></tr><tr><td><a href="/drugs/DB00205">Pyrimethamine</a></td><td>Pyrimethamine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Quinidine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Quinidine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00468">Quinine</a></td><td>Quinine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00243">Ranolazine</a></td><td>Ranolazine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, rasagiline.</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Rifabutin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB01201">Rifapentine</a></td><td>Rifapentine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Ritonavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Ritonavir may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00953">Rizatriptan</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00118">S-Adenosylmethionine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>Saquinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB01037">Selegiline</a></td><td>Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Selegiline.</td></tr><tr><td><a href="/drugs/DB01104">Sertraline</a></td><td>Tramadol increases the risk of serotonin syndrome and seizures. Sertraline may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Sertraline may decrease the effect of Tramadol by decreasing active metabolite production.</td></tr><tr><td><a href="/drugs/DB01105">Sibutramine</a></td><td>Sibutramine may incrase the serotonergic effect of the Tramadol. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB06268">Sitaxentan</a></td><td>Sitaxsentan may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00669">Sumatriptan</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may decrease the metabolism and clearance of tramadol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of tramadol if telithromycin is initiated, discontinued or dose changed.
</td></tr><tr><td><a href="/drugs/DB00857">Terbinafine</a></td><td>Terbinafine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00759">Tetracycline</a></td><td>Tetracycline may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>Thioridazine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00208">Ticlopidine</a></td><td>Ticlopidine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, tranylcypromine. Tranylcypromine may decrease the effect of tramadol by decreasing active metabolite production.</td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The use of two serotonin modulators, such as trazodone and tramadol, may increase the risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Tramadol may increase the risk of serotonin syndrome and seizures.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Tramadol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Verapamil may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tramadol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tramadol if voriconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00315">Zolmitriptan</a></td><td>The use of two serotonin modulators, such as zolmitriptan and tramadol, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Oral administration of tramadol hydrochloride with food does not significantly affect its rate or extent of absorption, therefore, tramadol hydrochloride can be administered without regard to food.</li></ul></td></tr></tbody></table>